Treatment of relapsed malignant glioma with an adenoviral vector containing the herpes simplex thymidine kinase gene followed by ganciclovir

Molecular Therapy

Volumn 7, Issue 6, 2003, Pages 851-858

  Smitt, Peter Sillevis ^a   Driesse, Maarten ^a   Wolbers, John ^b   Kros, Max ^a   Avezaat, Cees ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Adenovirus; Astrocytoma; Ganciclovir; Gene therapy; Glioblastoma; HSV tk; Oligodendroglioma

Indexed keywords

ADENOVIRUS VECTOR; CYCLOPHOSPHAMIDE; GANCICLOVIR; PREDNISOLONE; PROCARBAZINE; TEMOZOLOMIDE; THYMIDINE KINASE; VINCRISTINE;

ADULT; ANEMIA; AUTOPSY; CANCER GRADING; CANCER GROWTH; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG TOLERABILITY; DYSPHASIA; FEMALE; FEVER; GLIOBLASTOMA; HERPES SIMPLEX; HUMAN; HYPONATREMIA; MALE; MAXIMUM TOLERATED DOSE; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHLEBITIS; POSTOPERATIVE PERIOD; PROMOTER REGION; REVIEW; SAFETY; SEPSIS; SURGICAL WOUND; THROMBOCYTOPENIA; URINARY TRACT INFECTION; VIRAL GENE THERAPY; VOMITING;

ADENOVIRIDAE; HERPES; SIMPLEXVIRUS;

EID: 0037812853     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1525-0016(03)00100-X     Document Type: Article

References (49)

1. Barker, F. G. 2nd, et al. (1998). Survival and functional status after resection of recurrent glioblastoma multiforme. Neurosurgery 42: 709-720; discussion 720-723.
2. Berger, M. W., Tucker, A., Spence, A., and Winn, H. R. (1992). Reoperation for glioma. Clin. Neurosurg. 39: 177-186.
3. Chen, S.-H., Shine, H. D., Goodman, J. C., Grossman, R. G., and Woo, S. L. C. (1994). Gene therapy for brain tumors: Regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc. Natl. Acad. Sci. USA 91: 3054-3057.
4. Crumpacker, C. S. (1996). Ganciclovir. N. Engl. J. Med. 335: 721-729.
5. Culver, K. W., et al. (1992). In vivo gene transfer with retroviral vector producer cells for treatment of experimental brain tumors. Science 256: 1550-1552.
6. Dewey, R. A., et al. (1999). Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: Implications for clinical trials. Nat. Med. 5: 1256-1263.
7. Dirks, P., Bernstein, M., Muller, P. J., and Tucker, W. S. (1993). The value of reoperation for recurrent glioblastoma. Can. J. Surg. 36: 271-275.
8. Driesse, M. J., et al. (2000). Intra-CSF administered recombinant adenovirus causes an immune response-mediated toxicity. Gene Ther. 7: 1401-1409.
9. Driesse, M. J., et al. (1999). Distribution of recombinant adenovirus in the cerebrospinal fluid of nonhuman primates. Hum. Gene Ther. 10: 2347-2353.
10. Driesse, M. J., et al. (1998). Intracerebral injection of adenovirus harboring the HSVtk gene combined with ganciclovir administration: Toxicity study in nonhuman primates. Gene Ther. 5: 1122-1130.
11. Friedman, H. S., et al. (1999). Irinotecan therapy in adults with recurrent or progressive malignant glioma. J. Clin. Oncol. 17: 1516-1525.
12. Goodman, J. C., et al. (1996). Adenoviral-mediated thymidine kinase gene transfer into the primate brain followed by systemic ganciclovir: Pathologic, radiologic, and molecular studies. Hum. Gene Ther. 7: 1241-1250.
13. Grill, J., et al. (2001). Combined targeting of adenoviruses to integrins and epidermal growth factor receptors increases gene transfer into primary glioma cells and spheroids. Clin. Cancer Res. 7: 641-650.
14. Hamel, W., Magnelli, L., Chiarugi, V. P., and Israel, M. A. (1996). Herpes simplex virus thymidine kinase/ganciclovir-mediated apoptotic death of bystander cells. Cancer Res. 56: 2697-2702.
15. Harsh, G. R., et al. (1987). Reoperation for recurrent glioblastoma and anaplastic astrocytoma. Neurosurgery 21: 615.
16. Izquierdo, M., et al. (1996). Human malignant brain tumor response to herpes simplex thymidine kinase (HSVtk)/ganciclovir gene therapy. Gene Ther. 3: 491-495.
17. Jacobs, A., et al. (2001). Positron-emission tomography of vector-mediated gene expression in gene therapy for gliomas. Lancet 358: 727-729.
18. Judy, K. D., and Eck, S. L. (2002). The use of suicide gene therapy for the treatment of malignancies of the brain). Gene Therapy of Cancer (In E. C. Lattime, and L. G. Stanton, Eds.), Academic Press, San Diego.
19. Klatzmann, D., et al. (1998). A phase I/II dose-escalation study of herpes simplex virus type 1 thymidine kinase "suicide" gene therapy for metastatic melanoma. Study Group on Gene Therapy of Metastatic Melanoma. Hum. Gene Ther. 9: 2585-2594.
20. Kramm, C. M., et al. (1997). Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy. Hum. Gene Ther. 8: 2057-2068.
21. Kruyt, F. A., and Curiel, D. T. (2002). Toward a new generation of conditionally, replicating adenoviruses: Pairing tumor selectivity with maximal oncolysis. Hum. Gene Ther. 13: 485-495.
22. Lowenstein, P. R., and Castro, M. G. (2002). Progress and challenges in viral vector-mediated gene transfer to the brain. Curr. Opin. Mol. Ther. 4: 359-371.
23. Marshall, E. (1999). Gene therapy death prompts review of adenovirus vector. Science 286: 2244-2245.
24. Miller, C. R., et al. (1998). Differential susceptibility of primary and established human glioma cells to adenovirus infection: Targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer. Cancer Res. 58: 5738-5748.
25. Nanda, D., et al. (2002). Imaging expression of adenoviral HSV1-tk suicide gene transfer using the nucleoside analogue FIRU. Eur. J. Nucl. Med. Mol. Imaging 29: 939-947.
26. Nguyen, J. B., Sanchez-Pernaute, R., Cunningham, J., and Bankiewicz, K. S. (2001). Convection-enhanced delivery of AAV-2 combined with heparin increases TK gene transfer in the rat brain. NeuroReport 12: 1961-1964.
27. Packer, R. J., et al. (2000). Treatment of progressive or recurrent pediatric malignant supratentorial brain tumors with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration. J. Neurosurg. 92: 249-254.
28. Puumalainen, A. M., et al. (1998). Beta-galactosidase gene transfer to human malignant glioma in vivo using replication-deficient retroviruses and adenoviruses. Hum. Gene Ther. 9: 1769-1774.
29. Rainov, N. G. (2000). A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum. Gene Ther. 11: 2389-2401.
30. Ram, Z., et al. (1997). Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat. Med. 3: 1354-1361.
31. Ram, Z., et al. (1994). The effect of thymidine kinase transduction and ganciclovir therapy on tumor vasculature and growth of 9L gliomas in rats. J. Neurosurg. 81: 256-260.
32. Salcman, M. (1995). Glioblastoma and malignant astrocytoma). Brain Tumors (In A. H. Kaye, and E. R. Laws, Eds.), pp. 449-479. Churchill Livingstone, New York.
33. Sandmair, A. M., et al. (2000). Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses. Hum. Gene Ther. 11: 2197-2205.
34. Shand, N., et al. (1999). A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. GLI328 European-Canadian Study Group. Hum. Gene Ther. 10: 2325-2335.
35. Shine, H. D., et al. (1997). Neurotoxicity of intracerebral injection of a replication-defective adenoviral vector in a semipermissive species (cotton rat). Gene Ther. 4: 275-279.
36. Smith, J. G., et al. (1997). Intracranial administration of adenovirus expressing HSV-TK in combination with ganciclovir produces a dose-dependent, self-limiting inflammatory response. Hum. Gene Ther. 8: 943-954.
37. CBTRUS. (1998). 1997 Annual Report. CBTRUS, Chicago.
38. Surawicz, T. S., Davis, F., Freels, S., Laws, E. R. Jr., and Menck, H. R. (1998). Brain tumor survival: Results from the National Cancer Data Base. J. Neurooncol. 40: 151-160.
39. Touraine, R. L., Ishii-Morita, H., Ramsey, W. J., and Blaese, R. M. (1998). The bystander effect in the HSVtk/ganciclovir system and its relationship to gap junctional communication. Gene Ther. 5: 1705-1711.
40. Trask, T. W., et al. (2000). Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors. Mol. Ther. 1: 195-203.
41. Valery, C. A., et al. (2002). Long-term survival after gene therapy for a recurrent glioblastoma. Neurology 58: 1109-1112.
42. van Beusechem, V. W., et al. (2002). Efficient and selective gene transfer into primary human brain tumors by using single-chain antibody-targeted adenoviral vectors with native tropism abolished. J. Virol. 76: 2753-2762.
43. Vile, R. G., et al. (1997). Generation of an anti-tumour immune response in a non-immunogenic tumour: HSVtk killing in vivo stimulates a mononuclear cell infiltrate and a Th1 -like profile of intratumoural cytokine expression. Int. J. Cancer 71: 267-274.
44. Vincent, A. J., et al. (1997). Preclinical testing of recombinant adenoviral herpes simplex virus thymidine kinase gene therapy for central nervous system malignancies. Neurosurgery 41: 442-451.
45. Vincent, A. J., et al. (1996). Herpes simplex virus thymidine kinase gene therapy for rat malignant brain tumors. Hum. Gene Ther. 7: 197-205.
46. Vincent, A. J. P. E., et al. (1996). Treatment of leptomeningeal metastases in a rat model using a recombinant adenovirus containing the HSV-tk gene. J. Neurosurg. 85: 648-654.
47. Visser, O., Coebergh, J. W. W., Schouten, L. J., and van Dijck, J. A. A. M. (1998). Incidence of cancer in the Netherlands 1995. Vereniging van Integrale Kankercentra, Utrecht.
48. Yung, W . K., et al. (1999). Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J. Clin. Oncol. 17: 2762-2771.
49. Zaiss, A. K., et al. (2002). Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors. J. Virol. 76: 4580-4590.